INTRODUCTION
In April 2007, Australia began vaccinating women aged 12e27 years against human papillomavirus (HPV) genotypes 6, 11, 16 and 18 using the quadrivalent HPV vaccine (Gardasil; CSL Biotherapies, Melbourne Victoria, Australia). We previously reported that by the end of 2008, presentations of genital warts (GW) at the Melbourne Sexual Health Centre (MSHC) had halved in women younger than 28 years, declined to a lesser degree in heterosexual men but not changed in homosexual men or women aged 28 years or older. 1 By the end of 2009, an Australia-wide surveillance programme using data from eight sexual health centres 2 confirmed our initial observations and also showed that the changes in younger women were restricted to Australians who were eligible for the free vaccine and were not seen in non-residents. 2 By the end of 2009, however, the decline in younger women had slowed substantially raising doubts as to whether the vaccination programme would eventually eliminate GWs or merely reduce their incidence. 2 Furthermore, the national data do not currently include the number of sexual partners so they cannot be adjusted for any changes in sexual risk that may explain changes seen in GWs presentations.
In this analysis, we update the trends in GWs at MSHC to the end of June 2011, adjusting for sexual risk, and we explore trends in women young enough to have been vaccinated at school before a significant proportion may have become sexually active. 3 
METHODS
We extracted data from the patient management database to investigate the proportion of new clients who were diagnosed with GWs attending MSHC between 1 July 2004 and 30 June 2011. MSHC is the major public sexual health clinic serving Melbourne, a city of 4 million people. The Centre provides a walk-in triage service that prioritises access to the centre for clients who belong to risk groups or who have symptoms, and the same triage process has been in place since 2001. 4 Referrals are not required and services are free of charge. GWs are not a notifiable infection in any state or territory of Australia.
Clinical and epidemiological data are routinely entered into the clinic electronic database during consultations with every new client. These data include the diagnosis and the number and gender of sexual partners in the previous 12 months. Demographic data include the country of birth and, for those born overseas, year of arrival in Australia. In this analysis, those born outside Australia and who had arrived $3 years before their visit were classified as 'non-residents' as they were unlikely to be eligible for the HPV vaccination programme, which was only available to Australian citizens or permanent residents. Obtaining Australian citizenship or permanent residence takes at least 3 years. 5 From 2009, women were asked if they had ever had the HPV vaccine.
The quadrivalent HPV vaccine was made available in Australia free of charge from April 2007 to girls aged 12 and 13 years in an ongoing school-based programme and to a catch-up group of 13e18-year-old girls in a largely school-based programme until the end of 2009. From July 2007, it became available free of charge through general practitioners and community immunisation clinics for young women, aged up to and including 26 years, but was no longer available to this group after the end of 2009. There were no programmes for men or older women, although the quadrivalent vaccine was available for approximately A$450 for men aged 9e26 years and for women aged 9e45 years. The bivalent vaccine (Cervarix; GlaxoSmithKline Biologicals, Rixensart, Belgium) is also commercially available for women of the same age but is not subsidised.
Statistical analysis
In figure 1 , the proportion of new clients with a GW diagnosis was calculated by dividing the number of GW diagnoses by the number of new clients seen in the relevant risk group in 6-month periods. ORs and 95% CIs for a diagnosis of warts in each additional 12-month period after 1 July 2007 were calculated using logistic regression and adjusted for the number of sexual partners in the previous 12 months. The same analysis was also undertaken for the 3-year period from 1 July 2004. These analyses were stratified by different age groups and risk groups. All calculations were performed in Stata V.11 (StataCorp).
Our primary objective was to determine the population effect of the HPV vaccination programme in Melbourne in women and in men through herd immunity, so we excluded non-residents from all but not the first logistic regression because the majority of their new sexual partners in Australia are also recent arrivals. 6 We examined three groups of women defined by their age on the day they attended (<21, 21e29 and $30 years). No women The HPV vaccine registry estimated vaccine coverage at the end of the catch-up period at 80% for two doses and 73% for three doses for girls aged 12e13 years. Coverage was lower with increasing age, with two-and three-dose coverage, respectively, for women aged 16e17 years was 75% and 72% and for women aged 18e19 years it was 53% and 30%; for women aged 20e26 years it was 38% and 42%. 7 Coverage rates for three doses in girls aged 15 years of age in 2009 were somewhat higher in Victoria (76.1%) than in Australia as a whole (70.7%). 8 The study was approved by the Alfred Hospital ethics committee as involving 'negligible risk' and did not require a formal ethics submission. 
RESULTS

DISCUSSION
We have demonstrated the near disappearance of GWs in heterosexual women and men <21 years of age attending a large sexual health service drawn from a population that started vaccinating girls and young women for HPV only 4 years ago. This reduction in women and men under 21 years of age has occurred without any corresponding reduction in GWs in women over 30 years of age, MSM and non-residents. None of these latter groups were eligible for the free vaccination programme. Our analyses were adjusted for the number of sexual partners in the previous 12 months adding strength to the findings. The data provide the first evidence that a vaccination programme with a 70% coverage of young women may lead to the near disappearance of GWs from the heterosexual population and suggest that the reproductive rate of HPV types 6 and 11 in young Australians is now below one. Unfortunately, the data also indicate that MSM, whose rate of anal cancer is at least as high as cervical cancer in women, are receiving no benefit from the current HPV vaccination programme. 9 Our study has a number of limitations that are important to consider in interpreting the results. Our data come from a single centre and the findings could be different in other parts of Australia. Furthermore, our findings could be explained by unmeasured confounding. We consider these possibilities to be unlikely for a number of reasons including the similarity between our earlier findings to the end of 2008 1 and the findings of the Australia-wide surveillance programme, 2 the fact that our data have been adjusted for sexual behaviour which is the most important predictor of GW, the very large effect size that we have demonstrated and finally the absence of a decline in GW in unvaccinated groups in any risk group before July 2007. In addition, previous work has shown an increasing prevalence of other sexually transmitted infections among heterosexuals attending MSHC, which would make a fall in GW without vaccination even more unlikely 10 11 Recent data from Australia 12 demonstrate a similar decline in rates of high-grade cervical abnormalities in young women, suggesting that the prevalence of HPV types 16 and 18 may also be declining rapidly. This effect was most apparent in data from 19 158 women aged <18 years who were screened over 7 years (Australian guidelines throughout this period did not recommend cervical screening before 18 years of age).
The contrast between the marked decline in presentations of GWs in women <21 years of age and the less marked decline in those aged 21e29 years, raises a number of important hypotheses. By 2011, all the women aged 21e29 years would have been eligible for the free catch-up HPV vaccine programme, but we did not see a similar decline in GWs to that seen in younger women. One possibility is that a higher proportion women aged 21e29 years were already infected with HPV type 6 or 11 and that there may be a substantial delay in the appearance of GWs after HPV infection. Previous studies indicated that genital warts appear a mean of 2.9 months (IQR 0e5.7 months) after the detection of HPV type 6/11 DNA or a mean of 2.8 months (range 0e8 months) after sex with someone with warts. 13 14 However, a more recent study by Garland et al 15 reported warts appearing up to 45 months after the first detection of HPV type 6 DNA. This suggests that a significant 'wash out' period may exist after HPV vaccination when lesions could emerge from HPV infection acquired before vaccination. In support of this point, we saw the decline in GW continuing until June 2011 in women who reported having received the HPV vaccine, which was only provided free up to the end of 2009. There are two further possible explanations for the difference in rate of decline between the two younger age groups in women. The first may be that herd immunity is weaker in the older women (21e29 years of age) who tend on average to have sex with men 6319 individuals were not born in Australia but did not complete year of arrival at registration. *Non-residents were those not born in Australia, whose year of arrival was within 3 years of consultation. All analyses except the first row exclude non-residents unless '*' is shown. HPV, human papillomavirus; MSM, men who have sex with men; MSW, men who have sex with women. 1e5 years older than they are. 16 Second, the significantly lower HPV vaccine coverage during the catch-up programme for women older than school age may have reduced the population effectiveness of the vaccine. 7 We conclude that the heterosexual transmission of GWs will become rare in Australia as a result of the HPV vaccination programme. Addressing the continuing transmission of warts among MSM will be the next challenge for health policy makers. 
